Breaking News Instant updates and real-time market news.

OBSV

ObsEva

$17.21

2.68 (18.44%)

07:48
06/19/18
06/19
07:48
06/19/18
07:48

ObsEva price target raised to $31 from $23 at BMO Capital

BMO Capital analyst Peter Lawson raised his price target on ObsEva to $31 following the positive OBE2109 EDELWEISS data in endometriosis, saying the results "confirm comparable high dose efficacy to leader Elagolix" with better balanced pain benefit. Lawson adds that the 5-month bone data expected in Q4 of this year will further support the OBE2109 preferable profile, leading to the initiation of a Phase 3 endometriosis study in Q1 of 2019. The analyst is also positive on additional upside coming from the Nolasiban live birth rate data and OBE022 phase 2 read-out in Q4, keeping his Outperform rating on ObsEva.

  • 20

    Jun

OBSV ObsEva
$17.21

2.68 (18.44%)

06/18/18
BMOC
06/18/18
NO CHANGE
Target $31
BMOC
Outperform
ObsEva positive EDELWEISS data de-risks Phase 3 studies, says BMO Capital
BMO Capital analyst Do Kim raised the price target for ObsEva to $31 from $23, while reiterating an Outperform rating on the shares, following positive OBE2109 EDELWEISS data in endometriosis. He believes the data confirms OBE2109 benefit and further de-risks Phase 3 studies in uterine fibroid. The analyst also raised his probability of success to 70% and said he expects 6-month bone data in Q4 to further support OBE2109 preferable profile, and initiation of Phase 3 endometriosis study in Q1. In the interim, additional upside could come from Nolasiban live birth rate data and OBE022 Phase 2 data in Q4.
06/18/18
BMOC
06/18/18
NO CHANGE
Target $31
BMOC
Outperform
ObsEva price target raised to $31 from $23 at BMO Capital
BMO Capital analyst Do Kim raised the price target on ObsEva to $31 from $23 after the company reported 12-week results from its Phase 2b clinical trial of linzagolix for the treatment of endometriosis-associated pain. Kim maintains an Outperform rating on ObsEva shares.
06/12/18
BMOC
06/12/18
INITIATION
Target $23
BMOC
Outperform
ObsEva initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim initiated ObsEva with an Outperform rating and a price target of $23, saying the company's OBE2109 offers "the best drug profile among GnRH antagonists" which will allow it to capture a "meaningful market share in uterine fibrosis and endometriosis". The analyst adds that ObsEva's Nolasiban is underappreciated despite the positive Phase 3 data, and the live birth results in Q4 may lead to investors' reassessment of the treatment.
02/28/18
HCWC
02/28/18
NO CHANGE
Target $27
HCWC
Buy
ObsEva target raised to $27 on positive nolasiban data at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ObsEva to $27 citing the positive top-line data from the first pivotal Phase 3 trial of its most advanced clinical-stage candidate, nolasiban. The analyst views the results as statistically significant and clinically meaningful. He reiterates a Buy rating on ObsEva.

TODAY'S FREE FLY STORIES

APYX

Apyx Medical

$7.93

0.005 (0.06%)

13:25
03/18/19
03/18
13:25
03/18/19
13:25
Conference/Events
Apyx Medical management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

T

AT&T

$30.77

0.09 (0.29%)

13:24
03/18/19
03/18
13:24
03/18/19
13:24
Periodicals
Kevin Tsujihara ousted as Warner Bros. CEO, CNBC reports »

Kevin Tsujihara has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 20

    May

CXP

Columbia Property

$21.99

-0.13 (-0.59%)

13:21
03/18/19
03/18
13:21
03/18/19
13:21
Conference/Events
Columbia Property management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

BSX

Boston Scientific

$37.77

-2.38 (-5.93%)

13:20
03/18/19
03/18
13:20
03/18/19
13:20
Options
Quarter million dollar block of calls sold to open in Boston Scientific »

Quarter million dollar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 28

    May

MIK

Michaels

$11.72

0.04 (0.34%)

, DSW

DSW

$25.05

-0.34 (-1.34%)

13:19
03/18/19
03/18
13:19
03/18/19
13:19
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MIK

Michaels

$11.72

0.04 (0.34%)

DSW

DSW

$25.05

-0.34 (-1.34%)

HDS

HD Supply

$42.88

-0.12 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

REGN

Regeneron

$408.15

-6.03 (-1.46%)

, DERM

Dermira

$12.46

5.63 (82.43%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
On The Fly
Dermira rises, Regeneron slips on eczema treatment study results »

Shares of Dermira (DERM)…

REGN

Regeneron

$408.15

-6.03 (-1.46%)

DERM

Dermira

$12.46

5.63 (82.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
03/18/19
03/18
13:17
03/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
03/18/19
03/18
13:16
03/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBCP

Home Bancorp

$36.50

0.59 (1.64%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Hot Stocks
Home Bancorp CEO John Bordelon sells over $232K shares of company stock »

Home Bancorp CEO John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$31.38

0.69 (2.25%)

13:14
03/18/19
03/18
13:14
03/18/19
13:14
Periodicals
Elanco tells Bloomberg CEO not planing to sell shares at lockup »

Elanco CEO Jeffrey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

APEN

Apollo Endosurgery

$3.29

-0.06 (-1.79%)

13:13
03/18/19
03/18
13:13
03/18/19
13:13
Recommendations
Apollo Endosurgery analyst commentary  »

Piper says Apollo's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 18

    May

  • 28

    May

QQQ

Invesco QQQ Trust

$178.07

0.1542 (0.09%)

13:10
03/18/19
03/18
13:10
03/18/19
13:10
Options
50K Invesco QQQ Jun 188 - 192 call spreads sold at 95c »

50K Invesco QQQ Jun 188 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARS

Cars.com

$22.75

0.04 (0.18%)

13:05
03/18/19
03/18
13:05
03/18/19
13:05
Options
Cars.com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
03/18/19
03/18
13:05
03/18/19
13:05
General news
FOMC Forecast revisions »

FOMC Forecast revisions…

AIR

AAR Corp.

$35.01

0.92 (2.70%)

13:01
03/18/19
03/18
13:01
03/18/19
13:01
Hot Stocks
AAR awarded $10.8M order from USAF to produce cargo pallets »

AAR has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

MYL

Mylan

$28.32

0.24 (0.85%)

12:51
03/18/19
03/18
12:51
03/18/19
12:51
Hot Stocks
Mylan Institutional LLC initiates voluntary recall of Levoleucovorin Injection »

Mylan Institutional LLC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.99

0.03 (1.01%)

12:50
03/18/19
03/18
12:50
03/18/19
12:50
Recommendations
Ladenburg Thalmann analyst commentary at Barrington »

Ladenburg Thalmann price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$44.88

-0.19 (-0.42%)

12:49
03/18/19
03/18
12:49
03/18/19
12:49
Periodicals
Sanofi says working on plan to find new CEO, Reuters reports »

Sanofi is working on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 28

    Apr

ATVI

Activision Blizzard

, SUI

Sun Communities

12:46
03/18/19
03/18
12:46
03/18/19
12:46
On The Fly
Fly Insider: Activision, Zebra among week's notable insider transactions »

Welcome to "Fly Insider,"…

ATVI

Activision Blizzard

SUI

Sun Communities

VRTX

Vertex

ESGR

Enstar Group

PBF

PBF Energy

OPK

Opko Health

$2.48

-0.035 (-1.39%)

CVS

CVS Health

FANG

Diamondback Energy

D

Dominion

SIX

Six Flags

BCO

Brink's

BK

BNY Mellon

PLNT

Planet Fitness

TNDM

TNDM

TTD

Trade Desk

AMH

American Homes 4 Rent

ZBRA

Zebra Technologies

ANSS

Ansys

IBP`

IBP Inc

COST

Costco

ZGNX

Zogenix

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 25

    Mar

  • 25

    Mar

  • 25

    Mar

  • 02

    Apr

  • 04

    Apr

  • 09

    Apr

  • 10

    Apr

  • 16

    Apr

  • 16

    Apr

  • 17

    Apr

  • 25

    Apr

  • 01

    May

  • 07

    May

  • 09

    May

  • 28

    May

  • 30

    May

ACA

Arcosa

$31.98

0.03 (0.09%)

12:46
03/18/19
03/18
12:46
03/18/19
12:46
Initiation
Arcosa initiated at Stephens »

Arcosa initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 19

    Mar

SEDG

SolarEdge

$39.40

-0.57 (-1.43%)

12:45
03/18/19
03/18
12:45
03/18/19
12:45
Recommendations
SolarEdge analyst commentary at Vertical Group »

SolarEdge lost second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 20

    Mar

  • 21

    Mar

APHA

Aphria

$10.22

0.62 (6.46%)

12:45
03/18/19
03/18
12:45
03/18/19
12:45
Options
Aphria call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$202.24

3.97 (2.00%)

, SPGI

S&P Global

$205.03

1.91 (0.94%)

12:43
03/18/19
03/18
12:43
03/18/19
12:43
Hot Stocks
GSAM acquires S&P's Investment Advsisory Services; terms not disclosed »

Goldman Sachs Asset…

GS

Goldman Sachs

$202.24

3.97 (2.00%)

SPGI

S&P Global

$205.03

1.91 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$187.25

1.05 (0.56%)

12:36
03/18/19
03/18
12:36
03/18/19
12:36
Periodicals
Apple launches sixth developer beta of iOS 12.2, MacRumors reports »

Apple today plans to seed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$22.26

-0.67 (-2.92%)

12:35
03/18/19
03/18
12:35
03/18/19
12:35
Options
Scientific Games put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.